Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) Director Christian Henry sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $7.08, for a total value of $35,400.00. Following the completion of the sale, the director owned 19,310 shares in the company, valued at $136,714.80. The trade was a 20.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Ginkgo Bioworks Stock Up 11.2%
Shares of DNA opened at $7.85 on Friday. The stock has a market capitalization of $528.75 million, a P/E ratio of -1.57 and a beta of 1.76. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.37 and a twelve month high of $17.58. The company has a 50 day moving average of $7.59 and a 200-day moving average of $7.87.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.15. Ginkgo Bioworks had a negative net margin of 259.96% and a negative return on equity of 60.27%. The business had revenue of $20.16 million for the quarter, compared to analyst estimates of $24.05 million. On average, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -3.2 earnings per share for the current fiscal year.
Analyst Ratings Changes
View Our Latest Stock Analysis on Ginkgo Bioworks
More Ginkgo Bioworks News
Here are the key news stories impacting Ginkgo Bioworks this week:
- Positive Sentiment: Partnership with Eli Lilly: Ginkgo Datapoints will provide discovery-data generation services, including small-molecule data, to Lilly’s TuneLab network. TuneLab gives participating biotech companies access to AI and machine-learning models trained on Lilly’s proprietary research, potentially increasing Ginkgo’s visibility and future commercial opportunities. Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
- Positive Sentiment: Sector reaction: Ginkgo and other biotechnology companies involved in TuneLab agreements moved higher, suggesting investors viewed the collaboration as validation of AI-enabled drug discovery and Ginkgo’s data-generation capabilities. Twist Bio and Ginkgo rise after agreements with Lilly TuneLab
- Neutral Sentiment: Recent trading context: DNA recently finished a session at $7.06, up about 1%, while trading volume in the latest session was above its average. The stock remains near its 50-day and 200-day moving averages, indicating limited technical direction.
- Negative Sentiment: Analyst target reduced: The consensus price target was cut 22.22% to $7.14, leaving little implied upside relative to recent trading levels. MarketBeat data also shows a “Reduce” consensus, with an average target of $6.33 and several Sell ratings.
- Negative Sentiment: Director sold shares: Director Christian Henry sold 5,000 shares for approximately $35,400, reducing his direct ownership by 20.57%. Although the transaction is modest, insider selling can weigh on sentiment. Ginkgo Bioworks Director Sells 5,000 Shares
- Negative Sentiment: Losses remain substantial: Ginkgo’s latest quarter included a $0.75 per-share loss and $20.16 million in revenue, below the $24.05 million consensus estimate. Analysts expect a full-year loss of approximately $3.20 per share.
Hedge Funds Weigh In On Ginkgo Bioworks
Hedge funds and other institutional investors have recently bought and sold shares of the business. Prescott Group Capital Management L.L.C. acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at $4,503,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Ginkgo Bioworks by 28,457.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 228,744 shares of the company’s stock worth $1,901,000 after buying an additional 227,943 shares during the period. UBS Group AG lifted its holdings in Ginkgo Bioworks by 86.4% during the 4th quarter. UBS Group AG now owns 489,418 shares of the company’s stock worth $4,067,000 after buying an additional 226,861 shares during the period. Balance Capital Partners L.P. bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter valued at about $1,972,179. Finally, Renaissance Technologies LLC bought a new stake in shares of Ginkgo Bioworks in the 1st quarter valued at about $616,000. Institutional investors own 78.63% of the company’s stock.
About Ginkgo Bioworks
Ginkgo Bioworks is a biotechnology company that develops and operates a platform for programming cells. Its technology combines biological engineering, automation, software and data science to help customers design, build and test microorganisms and other biological systems for commercial applications.
The company provides cell-programming services and related tools to customers in areas including pharmaceuticals, agriculture, food and ingredients, industrial chemicals, materials and consumer products.
Featured Stories
- Five stocks we like better than Ginkgo Bioworks
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
